Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Recent findings from University of Texas highlight research in cancer vaccines
August 13th, 2008
According to a study from the United States, "For the current study, the authors sought to determine whether administration of multiple-dose granulocyte-macrophage-colony-stimulating factor (GM-CSF) could improve response to standard 23-valent polysaccharide pneumococcal vaccine (PPV) in patients with chronic lymphocytic leukemia (CLL). Patients were allocated randomly to receive PPV either alone or with 3 doses of GM-CSF (250 mu g) given before or after vaccination." "Serum was obtained before, 4 weeks after, and 12 weeks after vaccination for antibody determination. Thirty-two patients with CLL were given PPV They were randomized to receive 3 doses of GM-CSF either...
Source: Vaccine Weekly (2008-08-13)
|
